Investigational Drug Details
| Drug ID: | D263 |
| Drug Name: | Pancrelipase |
| Synonyms: | Pancrealipase; Pancreatic extract pancrelipase; Pancreatic protease; Pancreatin; Pancrelipase; Pancrelipase (amylase;lipase;protease) |
| Type: | Biological drug |
| DrugBank ID: | DB00085 |
| DrugBank Description: | Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010. For further information on the components of this mixture please visit , and . |
| PubChem ID: | -- |
| CasNo: | 53608-75-6 |
| Repositioning for NAFLD: | Yes |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | Dietary fat cleavage; Dietary protein cleavage; Dietary starch cleavage |
| DrugBank MoA: | Pancrelipase is used to replace the deficiency of pancreatic enzymes. As abovementioned, pancrelipase is formed by a mixture of lipase, protease, and amylase which are able to break down fat, protein, and starches, respectively, in the small intestine. For a more specific description of each mechanism of action, please visit , and . |
| DrugBank Pharmacology: | The major maldigestion/malabsorption problems arise from incomplete fat digestion. In clinical trials, the administration of pancrelipase as a mixture of amylase, lipase, and protease demonstrated a significant improvement in the coefficient of fat absorption and nitrogen absorption. These effects are accompanied by increased in body weight and body mass index. |
| DrugBank Indication: | The use of pancrelipase amylase is part of the pancreatic enzyme replacement therapy. This therapy is indicated for the treatment of pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis or any other medically defined pancreatic disease that might require it. Pancreatic diseases are associated with the deterioration of pancreatic parenchyma and of the dual physiological functions of the pancreas. Once established, pancreatic insufficiency results in malnutrition, weight loss, and steatorrhea. |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial on-going (JPRN-UMIN000006841) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0947 | JPRN-UMIN000006841 | Not selected | Recruiting | No Results Available | 05/12/2011 | 2 April 2019 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S08 | Lifestyle measures | Lifestyle intervention; weight loss; diet adaptation; dietary interventions; lifestyle modifications; Exercise | -- | -- | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00563 | 35046340 | Gan To Kagaku Ryoho | [A Case of Nonalcoholic Fatty Liver Disease after Pancreatoduodenectomy Which Reduced Tolerability of Chemotherapy for Postoperative Recurrence]. | Details |
| A01121 | 34863034 | J Hepatobiliary Pancreat Sci | Incidence and risk factors of nonalcoholic fatty liver disease after total pancreatectomy: A first multicenter prospective study in Japan. | Details |
| A09898 | 31569521 | Molecules | Separation and Lipid Inhibition Effects of a Novel Decapeptide from Chlorella pyenoidose. | Details |
| A19120 | 26748629 | J Hepatobiliary Pancreat Sci | Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreatic cancer? A randomized controlled trial. | Details |
| A20543 | 25904096 | J Gastroenterol | Pancrelipase with branched-chain amino acids for preventing nonalcoholic fatty liver disease after pancreaticoduodenectomy. | Details |
| A23421 | 23798362 | J Hepatobiliary Pancreat Sci | Effects of pancrelipase on nonalcoholic fatty liver disease after pancreaticoduodenectomy. | Details |
| A50462 | 35381910 | Surg Case Rep | Nonalcoholic fatty liver disease developed after pancreatoduodenectomy for solid pseudopapillary neoplasm in a 10-year-old girl: a case report. | Details |
| A51003 | 26726093 | Intern Med | Improvement of Pancreatic Tumor-induced NAFLD with Pancrelipase. | Details |